Dr Stella Lee (University of Pittsburgh, Pittsburgh, PA, US) spoke with touchRESPIRATORY around the SYNAPSE study, which investigated the efficacy and safety of mepolizumab in patients with chronic rhinosinusitis with nasal polyps (Clinical Trial Identifier: NCT03085797).
The abstract ‘Mepolizumab Improves Health Related Quality of Life for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study’ (ABSTRACT NUMBER: AB125) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions
- What is the rationale for the use of mepolizumab in the treatment of chronic rhinosinusitis with nasal polyps? (0:17)
- What did the SYNAPSE study data teach us about the efficacy and safety of mepolizumab in this treatment setting? (2:21)
- Could you tell us a little about the quality of life outcomes you studied in your recent analysis, and the findings of this study? (3:59)
Disclosures: Clinical trial funding and participation on advisory boards for: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi Regeneron.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
